Quick Answer
Sarepta Therapeutics, Inc. reported Stockholders Equity of $1.14 billion for fiscal year 2025.
Sarepta Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $1.14B | -25.3% |
| 2024 | $1.53B | +77.8% |
| 2023 | $859.34M | +123.2% |
| 2022 | $384.95M | -58.5% |
| 2021 | $928.01M | +21.8% |
| 2020 | $761.76M | -6.9% |
| 2019 | $818.19M | -20.7% |
| 2018 | $1.03B | +30.8% |
| 2017 | $789.22M | +134.4% |
| 2016 | $336.69M | +76.9% |
| 2015 | $190.35M | -23.1% |
| 2014 | $247.65M | +0.2% |
| 2013 | $247.19M | +99.9% |
| 2012 | $123.68M | +298.7% |
| 2011 | $31.02M | +1201.1% |
| 2010 | -$2.82M | -111.9% |
| 2009 | $23.63M | +50.2% |
| 2008 | $15.73M | — |
| 1980 | $0.00 | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.32B | +8.1% | -2.7% |
| June 30, 2025 | $1.36B | +26.0% | +18.8% |
| March 31, 2025 | $1.14B | +18.9% | -25.2% |
| December 31, 2024 | $1.53B | +77.8% | +25.1% |
| September 30, 2024 | $1.22B | +59.8% | +13.4% |
| June 30, 2024 | $1.08B | +45.3% | +12.1% |
| March 31, 2024 | $961.19M | +34.9% | +11.9% |
| December 31, 2023 | $859.34M | +123.2% | +12.4% |
- Sarepta Therapeutics, Inc. showed a decrease of -25.3% in Stockholders Equity compared to the prior fiscal year.
- The most recent figure is from Sarepta Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: